主动脉瓣反流患者行主动脉瓣置换术后的药物治疗
瑞典2006至2017年因主动脉瓣反流行主动脉瓣置换术且出院后存活6个月的2204例患者纳入研究,中位随访5.0年。肾素-血管紧张素系统抑制剂(aHR 0.71,95%CI 0.57-0.87)和他汀类(aHR 0.78,95%CI 0.62-0.99)与主要不良心血管事件风险降低相关,β受体阻滞剂与风险升高相关(aHR 1.35,95%CI 1.07-1.70)。
要点
- 肾素-血管紧张素系统抑制剂与他汀类分别与主要复合终点风险降低相关(aHR 0.71和0.78)。
- β受体阻滞剂与主要复合终点风险升高相关(aHR 1.35,95%CI 1.07-1.70)。
- 基线时68%使用肾素-血管紧张素系统抑制剂、80%使用β受体阻滞剂、35%使用他汀类。
核心结论
- 结果提示肾素-血管紧张素系统抑制剂和他汀类作为主动脉瓣反流患者主动脉瓣置换术后二级预防方案的一部分可能具有有益关联。
- β受体阻滞剂的作用需进一步研究。
研究设计与样本
- 纳入2006至2017年瑞典因主动脉瓣反流行瓣膜置换术且出院后6个月仍存活的所有患者,共2204例,中位随访5.0年(范围0.0-11.5)。
- 采用时间依赖多变量Cox回归模型,校正年龄、性别、患者特征、合并症、其他药物及主动脉瓣置换术年份。
- 主要结局为全因死亡、心肌梗死和卒中的复合终点。
- 基于年龄、性别、心力衰竭、低射血分数、高脂血症和高血压进行亚组分析。
主要发现
- 基线时68%的患者被配发肾素-血管紧张素系统抑制剂,80%被配发β受体阻滞剂,35%被配发他汀类。
- 肾素-血管紧张素系统抑制剂和他汀类的配发随时间下降,尤其在基线后第一年内,而他汀类的配发保持稳定。
- 肾素-血管紧张素系统抑制剂治疗与主要终点风险降低相关(aHR 0.71,95%CI 0.57-0.87)。
- 他汀类治疗与主要终点风险降低相关(aHR 0.78,95%CI 0.62-0.99)。
- β受体阻滞剂治疗与主要终点风险升高相关(aHR 1.35,95%CI 1.07-1.70)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Current clinical guidelines have no specific recommendations regarding medical therapy after surgical aortic valve replacement in patients with aortic regurgitation (AR). We studied the association between medical therapy with renin-angiotensin system (RAS) inhibitors, statins and β-blockers and long-term major adverse cardiovascular events. METHODS: All patients undergoing valve replacement due to AR between 2006 and 2017 in Sweden and alive 6 months after discharge were included. Time-dependent multivariable Cox regression models adjusted for age, sex, patient characteristics, comorbidities, other medications and year of surgical aortic valve replacement were used. Primary outcome was a composite of all-cause mortality, myocardial infarction and stroke. Subgroup analyses based on age, sex, heart failure, low ejection fraction, hyperlipidaemia and hypertension were performed. RESULTS: A total of 2204 patients were included [median follow-up 5.0 years (range 0.0-11.5)]. At baseline, 68% of the patients were dispensed RAS inhibitors, 80% β-blockers and 35% statins. Dispense of RAS inhibitors and β-blockers declined over time, especially during the first year after baseline, while dispense of statins remained stable. Treatment with RAS inhibitors or statins was associated with a reduced risk of the primary outcome [adjusted hazard ratio (aHR) 0.71, 95% confidence interval (CI) 0.57-0.87 and aHR 0.78, 95% CI 0.62-0.99, respectively]. The results were consistent in subgroups based on age, sex and comorbidities. β-Blocker treatment was associated with an increased risk for the primary outcome (aHR 1.35, 95% CI 1.07-1.70). CONCLUSIONS: The results indicate a potential beneficial association of RAS inhibitors and statins as part of a secondary preventive treatment regime after aortic valve replacement in patients with AR. The role of β-blockers needs to be further investigated.
引用
- Törngren C, Jonsson K, Hansson EC, et al. Medical therapy after surgical aortic valve replacement for aortic regurgitation. Eur J Cardiothorac Surg. 2023. PMID: 36748999. doi:10.1093/ejcts/ezad042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。